Trial Profile

First in Human Dose Escalation Study of YL-13027 Monotherapy in Subjects With Advanced Stage Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs YL 13027 (Primary)
Indications Advanced breast cancer; Carcinoma; Gallbladder cancer; Gastrointestinal cancer; Lung cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Shanghai Yingli Pharmaceutical

Most Recent Events

15 Nov 2021 Planned number of patients changed from 24 to 36.
15 Nov 2021 Planned End Date changed from 1 Mar 2020 to 30 Jun 2022.
08 Jun 2021 Results (n=13; as of 18 Jan 2021) presented at the 57th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com